135 related articles for article (PubMed ID: 15888758)
1. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma.
Jost LM; Stahel RA;
Ann Oncol; 2005; 16 Suppl 1():i60-1. PubMed ID: 15888758
[No Abstract] [Full Text] [Related]
2. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma.
Ann Oncol; 2001 Sep; 12(9):1211-2. PubMed ID: 11697827
[No Abstract] [Full Text] [Related]
3. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma.
Jost LM; Kloke O; Stahel RA;
Ann Oncol; 2005; 16 Suppl 1():i58-9. PubMed ID: 15888757
[No Abstract] [Full Text] [Related]
4. Relapsed large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
; Jost L
Ann Oncol; 2007 Apr; 18 Suppl 2():ii57-8. PubMed ID: 17491049
[No Abstract] [Full Text] [Related]
5. Newly diagnosed large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
; Jost L
Ann Oncol; 2007 Apr; 18 Suppl 2():ii55-6. PubMed ID: 17491048
[No Abstract] [Full Text] [Related]
6. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma.
Ann Oncol; 2001 Sep; 12(9):1209-10. PubMed ID: 11697826
[No Abstract] [Full Text] [Related]
7. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Tilly H; Vitolo U; Walewski J; da Silva MG; Shpilberg O; André M; Pfreundschuh M; Dreyling M;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii78-82. PubMed ID: 22997459
[No Abstract] [Full Text] [Related]
8. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Tilly H; Dreyling M;
Ann Oncol; 2008 May; 19 Suppl 2():ii67-9. PubMed ID: 18456774
[No Abstract] [Full Text] [Related]
9. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease.
McBride JA; Rodriguez J; Luthra R; Ordóñez NG; Cabanillas F; Pugh WC
Am J Surg Pathol; 1996 Feb; 20(2):193-201. PubMed ID: 8554109
[TBL] [Abstract][Full Text] [Related]
10. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease.
Jost LM; Stahel RA;
Ann Oncol; 2005; 16 Suppl 1():i54-5. PubMed ID: 15888755
[No Abstract] [Full Text] [Related]
11. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
12. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.
Marangon M; Stefoni V; Castellino A; Visco C; Tani M; Cox MC; Marasca R; Tecchio C; Devizzi L; Monaco F; Romano A; Rusconi C; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e321-e323. PubMed ID: 31080169
[No Abstract] [Full Text] [Related]
14. [Diagnosis and treatment of primary colorectal non-Hodgkin's lymphoma: analysis of 52 cases].
Huang S; Zheng ZX; Xu Q; Yuan XH
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):305-8. PubMed ID: 23985262
[TBL] [Abstract][Full Text] [Related]
15. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
17. Relapsed diffuse large B-cell lymphoma: clinical utility of cell of origin.
Vose JM
J Clin Oncol; 2011 Nov; 29(31):4065-6. PubMed ID: 21947831
[No Abstract] [Full Text] [Related]
18. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
19. A 64-year-old woman with cough and right middle lobe collapse. Diagnosis: diffuse large B-cell lymphoma.
Pilichowska M; Klepper S; Campbell G; Klein A; Ernst A; Finlay G
Chest; 2007 Nov; 132(5):1691-6. PubMed ID: 17998373
[No Abstract] [Full Text] [Related]
20. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
